Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Chemerin as a Mediator of Hypertension and Cardiometabolic Diseases (A Comprehensive Review)

McMillan R., Kirabo A.

Narrative Review on Type 2 Diabetes, Chronic Kidney Disease, published in Curr Hypertens Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Curr Hypertens Rep (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41457200
PMCID
PMC12745319
DOI
10.1007/s11906-025-01354-3

Abstract (original English)

Purpose Chemerin, a recently identified adipokine, has emerged as a critical mediator in multiple physiological systems with significant implications for human health and disease. This review synthesizes current knowledge on chemerin's multifaceted roles across cardiovascular, renal, immune, and metabolic processes. Acting through its primary receptor CMKLR1, chemerin influences sympathetic nervous system activity in key brain regions including the nucleus tractus solitarius and paraventricular nucleus, thereby regulating blood pressure and cardiovascular function. Recent findings In the kidneys, elevated chemerin levels correlate with declining renal function, serving as both a biomarker and pathogenic factor in chronic kidney disease progression and diabetic nephropathy. As an immune modulator, chemerin facilitates leukocyte recruitment, promotes macrophage polarization toward pro-inflammatory phenotypes, and enhances endothelial inflammation, establishing it as a pivotal link between metabolic dysregulation and chronic inflammatory states. Chemerin plays a central role in hypertension by altering endothelial function, renal function and sympathetic outflow. In metabolic regulation, chemerin influences adipocyte differentiation, glucose homeostasis, and central appetite control, connecting obesity with systemic inflammation and insulin resistance. The convergence of these div

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansCardiovascular DiseasesHypertensionIntercellular Signaling Peptides and ProteinsChemokinesMetabolic Syndrome

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research